Cargando...
Elucidating the Molecular Basis of Sorafenib Resistance in HCC: Current Findings and Future Directions
Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related mortality worldwide. Sorafenib is the first multi-tyrosine kinase inhibitor approved for HCC and it has represented the standard of care for advanced HCC for almost 10 years, offering a survival benefit when compared to pla...
Guardado en:
| Publicado en: | J Hepatocell Carcinoma |
|---|---|
| Autores principales: | , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Dove
2021
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8260177/ https://ncbi.nlm.nih.gov/pubmed/34239844 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/JHC.S285726 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|